A small, randomized cross-over trial showed Ivabradine may be a useful medication for hyperadrenergic POTS (Postural orthostatic tachycardia syndrome)
18 Feb, 2021 | 02:56h | UTCRandomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome – Journal of the American Academy of Cardiology (link to abstract – $ for full-text)
Commentaries: Existing heart failure drug may treat potential COVID-19 long-hauler symptom, study suggests – University of California – San Diego AND Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome – Ivabradine in POTS – American College of Cardiology
Commentary on Twitter
Our study showing ivabradine's benefit for POTS patients is out @JACCJournals. Also has implications for post-COVID 19 POTS (part of long haulers syndrome). Congrats to my co-first author/mentee @AdenaZadourian and the rest of my research team. @Dysautonomia @NIH @UCSDHealth pic.twitter.com/KGtzFh9CnT
— Pam R. Taub, MD (@PamTaubMD) February 15, 2021